[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342793-105":59,"doc-detail-342793-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-hippo-pathway-terminal-effector-tazwwtr1-mediates-oxaliplatin-sensitivity-in-p53-proficient-colon-cancer-cells","The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells","","YAP and TAZ, the terminal transcriptional activators of the Hippo pathway, are often upregulated in cancers and can influence tumor growth, stemness, and resistance to chemotherapy. In HCT116 colon cancer cells, oxaliplatin treatment downregulates core Hippo signaling and triggers nuclear accumulation of TAZ. TAZ is required for the resulting oxaliplatin sensitivity, largely independent of p73, and it depends on nuclear relocalization of TAZ. Verteporfin and CA3 show antagonistic effects with oxaliplatin in co-treatments, and TAZ sensitization to oxaliplatin depends on cellular p53 status, supporting a DNA-damage/apoptosis model.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-hippo-pathway-terminal-effector-tazwwtr1-mediates-oxaliplatin-sensitivity-in-p53-proficient-colon-cancer-cells/342793/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-hippo-pathway-terminal-effector-tazwwtr1-mediates-oxaliplatin-sensitivity-in-p53-proficient-colon-cancer-cells/342793.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"How does oxaliplatin affect Hippo pathway signaling in HCT116 cells?","Question",{"text":112,"@type":113},"Oxaliplatin leads to core Hippo pathway downregulation and promotes nuclear accumulation of TAZ.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Is TAZ required for oxaliplatin sensitivity, and does it depend on p73?",{"text":117,"@type":113},"TAZ is required for increased oxaliplatin sensitivity in HCT116 cells and the effect appears independent of p73, but it requires TAZ nuclear relocalization.",{"name":119,"@type":110,"acceptedAnswer":120},"How do YAP/TAZ-modulating drugs interact with oxaliplatin?",{"text":121,"@type":113},"Verteporfin and CA3 antagonize oxaliplatin’s effects when used in co-treatments.",{"name":123,"@type":110,"acceptedAnswer":124},"What role does p53 status play in TAZ-mediated sensitization to oxaliplatin?",{"text":125,"@type":113},"Across several colorectal cell lines, the sensitizing action of TAZ to oxaliplatin depends on the p53 status of the cells.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},342793,1790123935,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Slaninová et al. BMC Cancer (2024) 24:587 [https://doi.org/10.1186/s12885-024-12316-4](https://doi.org/10.1186/s12885-024-12316-4)  \nBMC Cancer  \n RESEARCH Open Access  \nThe Hippo pathway terminal effector TAZ/   WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells  \nVěra Slaninová1†, Lisa Heron‑Milhavet 1†, Mathilde Robin 1,2,3, Laura Jeanson1, Adam Aissanou1, Diala Kantar 1, Diego Tosi1,3, Laurent Bréhélin2, Céline Gongora4* and Alexandre Djiane1,4*  \nAbstract  \nYAP and TAZ, the Hippo pathway terminal transcriptional activators, are frequently upregulated in cancers. In tumor cells, they have been mainly associated with increased tumorigenesis controlling different aspects from cell cycle regulation, stemness, or resistance to chemotherapies. In fewer cases, they have also been shown to oppose cancer progression, including by promoting cell death through the action of the p73/YAP transcriptional complex, in par‑ ticular after chemotherapeutic drug exposure. Using HCT116 cells, we show here that oxaliplatin treatment led to core Hippo pathway down‑regulation and nuclear accumulation of TAZ. We further show that TAZ was required for the increased sensitivity of HCT116 cells to oxaliplatin, an effect that appeared independent of p73, but which required the nuclear relocalization ofTAZ. Accordingly, Verteporfin and CA3, two drugs affecting the activity ofYAP and TAZ, showed antagonistic effects with oxaliplatin in co‑treatments. Importantly, using several colorectal cell lines, we show that the sensitizing action of TAZ to oxaliplatin is dependent on the p53 status of the cells. Our results support thus an early action of TAZ to sensitize cells to oxaliplatin, consistent with a model in which nuclear TAZin the context of DNA damage and p53 activity pushes cells towards apoptosis.  \nKeywords Oxaliplatin, Colon cancer, Hippo signaling, TAZ, p53  \nIntroduction  \nColorectal cancer (CRC) is the third leading cause of cancer-related death worldwide [43]. Thirty percent of patients present synchronous metastases and 50–60% will develop metastases that will require chemotherapy.  \n†Věra Slaninová and Lisa Heron‑Milhavet contributed equally to this work.  \n*Correspondence:  \nCéline Gongora [celine.gongora@inserm.fr](celine.gongora@inserm.fr)[ ](celine.gongora@inserm.fr)Alexandre Djiane [alexandre.djiane@inserm.fr](alexandre.djiane@inserm.fr)  \n1 IRCM, Univ Montpellier, Inserm, ICM, Montpellier, France  \n2 LIRMM, Univ Montpellier, Inserm, CNRS, Montpellier, France  \n3 Fondazione Gianni Bonadonna, Milan, Italy  \n4 IRCM, Univ Montpellier, Inserm, ICM, CNRS, Montpellier, France  \nThe current management of advanced or metastatic CRCis based on fluoropyrimidine (5-FU), oxaliplatin and irinotecan as single agents or more often in combination (e.g. FOLFOX, FOLFIRI, or FOLFIRINOX; [63]). Chemotherapy is combined with targeted therapy including monoclonal antibodies against EGFR (e.g. cetuximab and panitumumab) or VEGF (bevacizumab), tyrosine kinase inhibitors (e.g. regorafenib), and immune checkpoint blockade agents for patients with MSI-High tumors (e.g. pembrolizumab; [63]).  \nOxaliplatin is a third-generation platinum antitumor compound with a 1,2-diaminocyclohexane (DACH) ligand [9, 44]. It induces mainly intra-strand crosslinks, but also inter-strand crosslinks and DNA–protein crosslinks that stop DNA replication and transcription, leading to apoptotic cell death [40, 61, 62]. Oxaliplatin  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line","cbCaiqkbcXk1ewZ3","https://ap.wps.com/l/cbCaiqkbcXk1ewZ3","pdf",8279212,18,"English","# Abstract\n# Introduction\n## Colorectal cancer burden and treatment\n## Oxaliplatin mechanism and resistance\n## Hippo pathway and TAZ/YAP roles","[{\"question\":\"How does oxaliplatin affect Hippo pathway signaling in HCT116 cells?\",\"answer\":\"Oxaliplatin leads to core Hippo pathway downregulation and promotes nuclear accumulation of TAZ.\"},{\"question\":\"Is TAZ required for oxaliplatin sensitivity, and does it depend on p73?\",\"answer\":\"TAZ is required for increased oxaliplatin sensitivity in HCT116 cells and the effect appears independent of p73, but it requires TAZ nuclear relocalization.\"},{\"question\":\"How do YAP/TAZ-modulating drugs interact with oxaliplatin?\",\"answer\":\"Verteporfin and CA3 antagonize oxaliplatin’s effects when used in co-treatments.\"},{\"question\":\"What role does p53 status play in TAZ-mediated sensitization to oxaliplatin?\",\"answer\":\"Across several colorectal cell lines, the sensitizing action of TAZ to oxaliplatin depends on the p53 status of the cells.\"}]","The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells | PDF",1790048258,45,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a266cc1d2f6719303c47dca2b7fab6b7.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/deb3ee79775bea36e3b0211962a1b20b.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08652fd6e08fff2727cb5c3bb3320407.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ad79b58b88afdc6c5c4f06529ee86b9.webp",980,1301]